Marker Therapeutics CFO Anthony Kim to depart Sept 30 as part of capital conservation measures

Marker Therapeutics, Inc.

CFO Anthony Kim separated effective September 30, 2022; part of company's capital conservation measures.
Severance benefits provided consistent with his Employment Agreement upon signing release.
No successor named; CEO Peter Hoang remains.
Company implementing cost-saving measures; CFO exit follows prior cost reduction steps.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Anthony Kim

Chief Financial Officer

MRKR · Marker Therapeutics, Inc.

Effective: 2022-09-30
Filed: September 27, 2022, 7:59 PM ET

Marker Therapeutics, Inc. (the “ Company ”) previously announced that the Company had separated Anthony Kim, Chief Financial Officer of the Company, effective September 30, 2022, as part of the Company’s capital conservation measures.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anthony Kim departed as Chief Financial Officer at Marker Therapeutics, Inc..

Action: separated
Role: Chief Financial Officer

Exact text from the filing

Marker Therapeutics, Inc. (the “ Company ”) previously announced that the Company had separated Anthony Kim, Chief Financial Officer of the Company, effective September 30, 2022, as part of the Company’s capital conservation measures.

View on SEC.gov

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-103164

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.